Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
89bio initiated with a Buy at BTIG » 05:50
07/23/20
07/23
05:50
07/23/20
05:50
ETNB

89bio

$32.97 /

-1.83 (-5.26%)

, AKRO

Akero Therapeutics

$36.94 /

+0.41 (+1.12%)

BTIG analyst Julian…

BTIG analyst Julian Harrison initiated coverage of 89bio (ETNB) with a Buy rating and $51 price target. Considering Akero Therapeutics (AKRO) is trading at an enterprise value double that of 89bio's and both are slated to begin Phase 2/3 development in the first half of 2021 with drugs in the same class for the same indication, 89bio is an attractive investment opportunity ahead of "derisked data" expected in late Q3, early Q4, Harrison tells investors in a research note.

ShowHide Related Items >><<
ETNB 89bio
$32.97 /

-1.83 (-5.26%)

AKRO Akero Therapeutics
$36.94 /

+0.41 (+1.12%)

ETNB 89bio
$32.97 /

-1.83 (-5.26%)

07/07/20 Chardan
89bio initiated with a Buy at Chardan
12/09/19 Oppenheimer
89bio initiated with an Outperform at Oppenheimer
12/09/19 SVB Leerink
89bio initiated with an Outperform at SVB Leerink
12/09/19 RBC Capital
89bio initiated with an Outperform at RBC Capital
AKRO Akero Therapeutics
$36.94 /

+0.41 (+1.12%)

07/20/20 H.C. Wainwright
Akero Therapeutics price target raised to $62 from $45 at H.C. Wainwright
07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
ETNB 89bio
$32.97 /

-1.83 (-5.26%)

AKRO Akero Therapeutics
$36.94 /

+0.41 (+1.12%)

  • 08
    Jul
  • 08
    Jul
  • 11
    Nov
ETNB 89bio
$32.97 /

-1.83 (-5.26%)

AKRO Akero Therapeutics
$36.94 /

+0.41 (+1.12%)

AKRO Akero Therapeutics
$36.94 /

+0.41 (+1.12%)

Hot Stocks
Akero announces publication of data from Phase 1 trial of efruxifermin » 11:05
07/21/20
07/21
11:05
07/21/20
11:05
AKRO

Akero Therapeutics

$38.42 /

+0.59 (+1.56%)

Akero Therapeutics…

Akero Therapeutics announced the publication of data in the journal Cell Reports Medicine from the Phase 1 clinical trial of efruxifermin, a fibroblast growth factor 21 analog, demonstrating its potential to modulate biomarkers associated with metabolic diseases, including NASH. In the article entitled, "AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients," researchers found that EFX demonstrated a sufficiently prolonged half-life of 3-3.5 days to support weekly dosing. In addition, with a variation in systemic concentration of only 2-fold when dosed weekly, treatment with EFX delivered larger and more consistent improvements in markers of insulin sensitivity and lipid metabolism than previously reported for FGF21 analogs, and it was reported to be generally well tolerated. Weekly administration of 70mg demonstrated larger metabolic effects than dosing every other week with 140mg, even though exposure to EFX was comparable. In patients dosed weekly with 70mg EFX in the Phase 1 study, treatment was associated with an increase in insulin sensitivity as demonstrated by reductions in HOMA-IR. This enhancement of insulin sensivity by EFX was replicated in NASH subjects and associated with better glycemic control, as recently disclosed for the BALANCED study. Treatment with EFX in the Phase 1 study was associated with amelioration of dyslipidemia, prevalent among type 2 diabetes and NASH patients, who are susceptible to cardiovascular disease. An improved lipoprotein profile was also evident with EFX treatment in the BALANCED study.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$38.42 /

+0.59 (+1.56%)

AKRO Akero Therapeutics
$38.42 /

+0.59 (+1.56%)

07/20/20 H.C. Wainwright
Akero Therapeutics price target raised to $62 from $45 at H.C. Wainwright
07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
AKRO Akero Therapeutics
$38.42 /

+0.59 (+1.56%)

  • 08
    Jul
AKRO Akero Therapeutics
$38.42 /

+0.59 (+1.56%)

AKRO Akero Therapeutics
$38.42 /

+0.59 (+1.56%)

Recommendations
Akero Therapeutics price target raised to $62 from $45 at H.C. Wainwright » 06:19
07/20/20
07/20
06:19
07/20/20
06:19
AKRO

Akero Therapeutics

$37.19 /

+ (+0.00%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce raised the firm's price target on Akero Therapeutics to $62 from $45 and keeps a Buy rating on the shares. THe analyst has increased confidence in efruxifermin in the setting of nonalcoholic steatohepatitis fibrosis and also added NASH cirrhosis to his model.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$37.19 /

+ (+0.00%)

AKRO Akero Therapeutics
$37.19 /

+ (+0.00%)

07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
AKRO Akero Therapeutics
$37.19 /

+ (+0.00%)

  • 08
    Jul
AKRO Akero Therapeutics
$37.19 /

+ (+0.00%)

AKRO Akero Therapeutics
$37.19 /

+ (+0.00%)

Over a month ago
Syndicate
Akero Therapeutics 5.23M share Secondary priced at $36.00 » 20:26
07/07/20
07/07
20:26
07/07/20
20:26
AKRO

Akero Therapeutics

$37.03 /

+1.94 (+5.53%)

The deal size was…

The deal size was increased to 5.23M shares from 4.75M shares and priced below the last closing price of $37.06. JPMorgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book running managers for the offering.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$37.03 /

+1.94 (+5.53%)

AKRO Akero Therapeutics
$37.03 /

+1.94 (+5.53%)

07/07/20 Chardan
Akero Therapeutics initiated with a Buy at Chardan
07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
AKRO Akero Therapeutics
$37.03 /

+1.94 (+5.53%)

  • 08
    Jul
AKRO Akero Therapeutics
$37.03 /

+1.94 (+5.53%)

AKRO Akero Therapeutics
$37.03 /

+1.94 (+5.53%)

Initiation
Akero Therapeutics initiated with a Buy at Chardan » 05:28
07/07/20
07/07
05:28
07/07/20
05:28
AKRO

Akero Therapeutics

$35.09 /

+1.96 (+5.92%)

Chardan analyst Michael…

Chardan analyst Michael Morabito initiated coverage of Akero Therapeutics with a Buy rating and $79 price target. The analyst believes efruxifermin has "best-in-class" potential in nonalcoholic steatohepatitis.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$35.09 /

+1.96 (+5.92%)

AKRO Akero Therapeutics
$35.09 /

+1.96 (+5.92%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
AKRO Akero Therapeutics
$35.09 /

+1.96 (+5.92%)

  • 08
    Jul
AKRO Akero Therapeutics
$35.09 /

+1.96 (+5.92%)

AKRO Akero Therapeutics
$35.09 /

+1.96 (+5.92%)

Syndicate
Akero Therapeutics files to sell 4.75M shares of common stock » 06:41
07/06/20
07/06
06:41
07/06/20
06:41
AKRO

Akero Therapeutics

$33.13 /

-0.36 (-1.07%)

JPM,Morgan Stanley,…

JPM,Morgan Stanley, Jefferies and Evercore ISI, are acting as joint book running managers for the offering.

ShowHide Related Items >><<
AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

On The Fly
Fly Intel: After-Hours Movers » 18:55
07/01/20
07/01
18:55
07/01/20
18:55
VERO

Venus Concept

$3.21 /

-0.275 (-7.89%)

, FEIM

Frequency Electronics

$9.15 /

+ (+0.00%)

, NUS

Nu Skin

$38.48 /

+0.35 (+0.92%)

, FORM

FormFactor

$29.34 /

+0.01 (+0.03%)

, AXNX

Axonics

$36.38 /

+1.26 (+3.59%)

, LDOS

Leidos

$93.34 /

-0.39 (-0.42%)

, CULP

Culp, Inc.

$10.03 /

+1.375 (+15.89%)

, BLFS

BioLife Solutions

$16.09 /

-0.22 (-1.35%)

, PLYA

Playa Hotels & Resorts

$3.66 /

+0.03 (+0.83%)

, AKRO

Akero Therapeutics

$33.49 /

+8.64 (+34.77%)

, MCD

McDonald's

$184.50 /

+0.15 (+0.08%)

, FIZZ

National Beverage

$63.51 /

+2.34 (+3.83%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VERO Venus Concept
$3.21 /

-0.275 (-7.89%)

PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

FORM FormFactor
$29.34 /

+0.01 (+0.03%)

FEIM Frequency Electronics
$9.15 /

+ (+0.00%)

CULP Culp, Inc.
$10.03 /

+1.375 (+15.89%)

BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

AXNX Axonics
$36.38 /

+1.26 (+3.59%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

VERO Venus Concept
$3.21 /

-0.275 (-7.89%)

03/31/20
Fly Intel: Top five analyst downgrades
03/31/20 Oppenheimer
Venus Concept downgraded to Perform at Oppenheimer as COVID-19 clouds outlook
03/31/20 Oppenheimer
Venus Concept downgraded to Perform from Outperform at Oppenheimer
01/09/20 Oppenheimer
Oppenheimer says has 'fundamentally positive' stance on Venus Concept
FEIM Frequency Electronics
$9.15 /

+ (+0.00%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

06/24/20 Citi
Nu Skin price target raised to $41 from $29 at Citi
05/07/20 Deutsche Bank
Nu Skin price target raised to $35 from $28 at Deutsche Bank
03/09/20 Deutsche Bank
Nu Skin downgraded to Hold from Buy at Deutsche Bank
02/13/20 DA Davidson
Nu Skin price target lowered to $35 from $42 at DA Davidson
FORM FormFactor
$29.34 /

+0.01 (+0.03%)

06/18/20 B. Riley FBR
FormFactor price target raised to $36 from $30 at B. Riley FBR
06/15/20 Stifel
FormFactor upgraded to Buy from Hold at Stifel
06/01/20 DA Davidson
FormFactor upgraded to Buy from Neutral at DA Davidson
06/01/20 DA Davidson
FormFactor upgraded to Buy from Neutral at DA Davidson
AXNX Axonics
$36.38 /

+1.26 (+3.59%)

04/21/20 Piper Sandler
Axonics price target lowered to $44 from $48 at Piper Sandler
04/14/20 Piper Sandler
Axonics next-gen INS not compatible with InterStim II leads, says Piper Sandler
04/08/20 Wells Fargo
Axonics price target lowered to $35 from $47 at Wells Fargo
03/05/20 Truist
Axonics price target raised to $48 from $38 at SunTrust
LDOS Leidos
$93.34 /

-0.39 (-0.42%)

06/11/20
Fly Intel: Top five analyst initiations
06/11/20 Baird
Baird starts Leidos at Outperform, sees growth poised to ramp next year
06/10/20 Baird
Leidos initiated with an Outperform at Baird
05/07/20
Fly Intel: Top five analyst initiations
CULP Culp, Inc.
$10.03 /

+1.375 (+15.89%)

05/28/20 Stifel
Culp upgraded to Buy from Hold at Stifel
02/19/20
Fly Intel: Top five analyst downgrades
02/19/20 Stifel
Culp, Inc. downgraded to Hold from Buy at Stifel
09/09/19 Raymond James
Culp, Inc. price target lowered to $18 from $22 at Raymond James
BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

05/15/20 Stephens
BioLife Solutions price target raised to $24 after 'strong' Q1 beat at Stephens
03/23/20 H.C. Wainwright
BioLife Solutions price target lowered to $17 from $26 at H.C. Wainwright
02/24/20 Lake Street
BioLife Solutions initiated with a Buy at Lake Street
02/19/20 Benchmark
BioLife Solutions initiated with a Buy at Benchmark
PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

04/29/20 Truist
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/29/20 Truist
Playa Hotels & Resorts downgraded to Hold from Buy at SunTrust
04/07/20 Citi
Playa Hotels & Resorts downgraded to Sell from Neutral at Citi
04/03/20 Deutsche Bank
Playa Hotels & Resorts price target lowered to $7 from $11 at Deutsche Bank
AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
MCD McDonald's
$184.50 /

+0.15 (+0.08%)

06/24/20 BMO Capital
McDonald's price target raised to $220 from $215 at BMO Capital
06/24/20 JPMorgan
McDonald's price target raised to $204 from $180 at JPMorgan
06/17/20 Morgan Stanley
McDonald's price target raised to $200 from $189 at Morgan Stanley
06/17/20 Truist
McDonald's price target raised to $208 from $195 at SunTrust
FIZZ National Beverage
$63.51 /

+2.34 (+3.83%)

05/18/20 Guggenheim
National Beverage price target raised to $38 from $34 at Guggenheim
11/18/19 Guggenheim
Coca-Cola's 'AHA' likely to take shelf space from LaCroix, says Guggenheim
11/11/19 Jefferies
National Beverage estimates and price target lowered at Jefferies
VERO Venus Concept
$3.21 /

-0.275 (-7.89%)

PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

FORM FormFactor
$29.34 /

+0.01 (+0.03%)

FIZZ National Beverage
$63.51 /

+2.34 (+3.83%)

CULP Culp, Inc.
$10.03 /

+1.375 (+15.89%)

BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

AXNX Axonics
$36.38 /

+1.26 (+3.59%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

  • 02
    Jul
  • 08
    May
  • 20
    Nov
MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

PLYA Playa Hotels & Resorts
$3.66 /

+0.03 (+0.83%)

NUS Nu Skin
$38.48 /

+0.35 (+0.92%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

LDOS Leidos
$93.34 /

-0.39 (-0.42%)

BLFS BioLife Solutions
$16.09 /

-0.22 (-1.35%)

AXNX Axonics
$36.38 /

+1.26 (+3.59%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

MCD McDonald's
$184.50 /

+0.15 (+0.08%)

FIZZ National Beverage
$63.51 /

+2.34 (+3.83%)

AKRO Akero Therapeutics
$33.49 /

+8.64 (+34.77%)

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:27
07/01/20
07/01
16:27
07/01/20
16:27
PFE

Pfizer

$33.75 /

+1.06 (+3.24%)

, BNTX

BioNTech

$64.14 /

-2.595 (-3.89%)

, FDX

FedEx

$156.86 /

+16.61 (+11.84%)

, STZ

Constellation Brands

$185.85 /

+11.415 (+6.54%)

, GM

General Motors

$24.95 /

-0.35 (-1.38%)

, FCAU

Fiat Chrysler

$9.90 /

-0.345 (-3.37%)

, VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

, HMC

Honda

$25.37 /

-0.19 (-0.74%)

, AAPL

Apple

$364.11 /

-0.35 (-0.10%)

, AKRO

Akero Therapeutics

$33.50 /

+8.65 (+34.81%)

, AXGN

AxoGen

$11.74 /

+2.48 (+26.78%)

, INO

Inovio

$19.73 /

-7.15 (-26.60%)

, SCS

Steelcase

$10.38 /

-1.69 (-14.00%)

The S&P began the third…

Open Full Text

ShowHide Related Items >><<
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

SCS Steelcase
$10.38 /

-1.69 (-14.00%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

HMC Honda
$25.37 /

-0.19 (-0.74%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

AXGN AxoGen
$11.74 /

+2.48 (+26.78%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

07/01/20 Goldman Sachs
Pfizer COVID-19 vaccine data 'encouraging,' says Goldman Sachs
06/30/20 H.C. Wainwright
BioNTech downgraded to Neutral from Buy at H.C. Wainwright
06/29/20 Mizuho
Pfizer resumed with a Buy at Mizuho
06/25/20 Piper Sandler
Aptevo Therapeutics price target raised to $24 from $18.50 at Piper Sandler
BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

07/02/20 Bryan Garnier
BioNTech price target raised to $62.50 from $50 at Bryan Garnier
06/25/20 H.C. Wainwright
BioNTech price target lowered to $63 from $69 at H.C. Wainwright
FDX FedEx
$156.86 /

+16.61 (+11.84%)

07/01/20
Fly Intel: Top five analyst upgrades
07/01/20 Cowen
FedEx price target raised to $167 from $156 at Cowen
07/01/20 Wells Fargo
FedEx price target raised to $179 from $153 at Wells Fargo
07/01/20 Baird
FedEx price target raised to $162 from $140 at Baird
STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

07/02/20 UBS
Constellation Brands price target raised to $208 from $192 at UBS
07/02/20 Jefferies
Constellation Brands price target raised to $238 from $224 at Jefferies
07/02/20 Citi
Constellation Brands price target raised to $200 from $176 at Citi
07/02/20 HSBC
Constellation Brands price target raised to $170 from $147 at HSBC
GM General Motors
$24.95 /

-0.35 (-1.38%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

06/30/20 UBS
Volkswagen price target raised to EUR 180 from EUR 140 at UBS
06/18/20 Jefferies
Volkswagen price target raised to EUR 135 from EUR 115 at Jefferies
06/16/20 BofA
Volkswagen downgraded to Neutral from Buy at BofA
HMC Honda
$25.37 /

-0.19 (-0.74%)

05/12/20 CLSA
Honda downgraded to Underperform from Outperform at CLSA
04/13/20 Goldman Sachs
Honda upgraded to Buy from Neutral at Goldman Sachs
03/30/20 UBS
Toyota and Honda upgraded to Buy, Nissan cut to Sell at UBS
AAPL Apple
$364.11 /

-0.35 (-0.10%)

06/26/20 Evercore ISI
Evercore upgrades Broadcom to Outperform, sees Apple sales driving upside
06/25/20 Wedbush
Wedbush boosts Apple target to $425, sees $2 trillion valuation in 2021
06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
06/23/20 Baird
Apple price target raised to $390 from $320 at Baird
AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
AXGN AxoGen
$11.74 /

+2.48 (+26.78%)

06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
05/07/20 Canaccord
AxoGen downgraded to Hold from Buy at Canaccord
INO Inovio
$19.73 /

-7.15 (-26.60%)

07/01/20
Fly Intel: Top five analyst downgrades
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
07/01/20 Roth Capital
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
SCS Steelcase
$10.38 /

-1.69 (-14.00%)

05/22/20 Benchmark
Steelcase initiated with a Buy at Benchmark
10/07/19 Raymond James
Raymond James steps away from three office furniture stocks
10/07/19 Raymond James
Steelcase downgraded to Market Perform from Strong Buy at Raymond James
09/23/19 Raymond James
Steelcase price target raised to $23 from $21 at Raymond James
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

SCS Steelcase
$10.38 /

-1.69 (-14.00%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

HMC Honda
$25.37 /

-0.19 (-0.74%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

AXGN AxoGen
$11.74 /

+2.48 (+26.78%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

  • 06
    Feb
  • 10
    Oct
VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

HMC Honda
$25.37 /

-0.19 (-0.74%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

VWAGY Volkswagen
$0.00 /

+ (+0.00%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

STZ Constellation Brands
$185.85 /

+11.415 (+6.54%)

SCS Steelcase
$10.38 /

-1.69 (-14.00%)

PFE Pfizer
$33.75 /

+1.06 (+3.24%)

INO Inovio
$19.73 /

-7.15 (-26.60%)

GM General Motors
$24.95 /

-0.35 (-1.38%)

FDX FedEx
$156.86 /

+16.61 (+11.84%)

FCAU Fiat Chrysler
$9.90 /

-0.345 (-3.37%)

BNTX BioNTech
$64.14 /

-2.595 (-3.89%)

AKRO Akero Therapeutics
$33.50 /

+8.65 (+34.81%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

AAPL Apple
$364.11 /

-0.35 (-0.10%)

Syndicate
Akero Therapeutics files $300M mixed securities shelf  16:10
07/01/20
07/01
16:10
07/01/20
16:10
AKRO

Akero Therapeutics

$33.20 /

+8.35 (+33.60%)

 
ShowHide Related Items >><<
AKRO Akero Therapeutics
$33.20 /

+8.35 (+33.60%)

AKRO Akero Therapeutics
$33.20 /

+8.35 (+33.60%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
AKRO Akero Therapeutics
$33.20 /

+8.35 (+33.60%)

AKRO Akero Therapeutics
$33.20 /

+8.35 (+33.60%)

AKRO Akero Therapeutics
$33.20 /

+8.35 (+33.60%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:07
07/01/20
07/01
12:07
07/01/20
12:07
PFE

Pfizer

$34.14 /

+1.45 (+4.44%)

, BNTX

BioNTech

$70.80 /

+4.065 (+6.09%)

, FDX

FedEx

$159.00 /

+18.75 (+13.37%)

, STZ

Constellation Brands

$187.97 /

+13.54 (+7.76%)

, GM

General Motors

$25.13 /

-0.17 (-0.67%)

, FCAU

Fiat Chrysler

$9.86 /

-0.38 (-3.71%)

, AKRO

Akero Therapeutics

$32.03 /

+7.18 (+28.89%)

, AXGN

AxoGen

$11.60 /

+2.34 (+25.27%)

, INO

Inovio

$21.08 /

-5.8 (-21.58%)

, SCS

Steelcase

$10.67 /

-1.4 (-11.60%)

The major averages are…

Open Full Text

ShowHide Related Items >><<
STZ Constellation Brands
$187.97 /

+13.54 (+7.76%)

SCS Steelcase
$10.67 /

-1.4 (-11.60%)

PFE Pfizer
$34.14 /

+1.45 (+4.44%)

INO Inovio
$21.08 /

-5.8 (-21.58%)

GM General Motors
$25.13 /

-0.17 (-0.67%)

FDX FedEx
$159.00 /

+18.75 (+13.37%)

FCAU Fiat Chrysler
$9.86 /

-0.38 (-3.71%)

AXGN AxoGen
$11.60 /

+2.34 (+25.27%)

AKRO Akero Therapeutics
$32.03 /

+7.18 (+28.89%)

PFE Pfizer
$34.14 /

+1.45 (+4.44%)

07/01/20 Goldman Sachs
Pfizer COVID-19 vaccine data 'encouraging,' says Goldman Sachs
06/30/20 H.C. Wainwright
BioNTech downgraded to Neutral from Buy at H.C. Wainwright
06/29/20 Mizuho
Pfizer resumed with a Buy at Mizuho
06/25/20 Piper Sandler
Aptevo Therapeutics price target raised to $24 from $18.50 at Piper Sandler
BNTX BioNTech
$70.80 /

+4.065 (+6.09%)

06/25/20 H.C. Wainwright
BioNTech price target lowered to $63 from $69 at H.C. Wainwright
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
FDX FedEx
$159.00 /

+18.75 (+13.37%)

07/01/20
Fly Intel: Top five analyst upgrades
07/01/20 Cowen
FedEx price target raised to $167 from $156 at Cowen
07/01/20 Wells Fargo
FedEx price target raised to $179 from $153 at Wells Fargo
07/01/20 Baird
FedEx price target raised to $162 from $140 at Baird
STZ Constellation Brands
$187.97 /

+13.54 (+7.76%)

07/01/20 BofA
BofA makes 14 additions, four deletions from US 1 list
06/17/20 JPMorgan
Constellation Brands added to Analyst Focus List at JPMorgan
06/01/20 Cowen
Constellation Brands price target raised to $205 from $160 at Cowen
05/20/20 MKM Partners
MKM Partners sees negative pre-announcement as likely from Constellation Brands
GM General Motors
$25.13 /

-0.17 (-0.67%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
General Motors price target raised to $33 from $29 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
FCAU Fiat Chrysler
$9.86 /

-0.38 (-3.71%)

06/30/20 UBS
Fiat Chrysler price target raised to EUR 9 from EUR 6 at UBS
06/22/20 Redburn
Fiat Chrysler upgraded to Buy from Neutral at Redburn
AKRO Akero Therapeutics
$32.03 /

+7.18 (+28.89%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
AXGN AxoGen
$11.60 /

+2.34 (+25.27%)

06/16/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
06/15/20 Cantor Fitzgerald
AxoGen assumed with an Overweight at Cantor Fitzgerald
05/07/20 Canaccord
AxoGen downgraded to Hold at Canaccord
05/07/20 Canaccord
AxoGen downgraded to Hold from Buy at Canaccord
INO Inovio
$21.08 /

-5.8 (-21.58%)

07/01/20
Fly Intel: Top five analyst downgrades
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
07/01/20 Roth Capital
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
SCS Steelcase
$10.67 /

-1.4 (-11.60%)

05/22/20 Benchmark
Steelcase initiated with a Buy at Benchmark
10/07/19 Raymond James
Raymond James steps away from three office furniture stocks
10/07/19 Raymond James
Steelcase downgraded to Market Perform from Strong Buy at Raymond James
09/23/19 Raymond James
Steelcase price target raised to $23 from $21 at Raymond James
STZ Constellation Brands
$187.97 /

+13.54 (+7.76%)

SCS Steelcase
$10.67 /

-1.4 (-11.60%)

PFE Pfizer
$34.14 /

+1.45 (+4.44%)

INO Inovio
$21.08 /

-5.8 (-21.58%)

GM General Motors
$25.13 /

-0.17 (-0.67%)

FDX FedEx
$159.00 /

+18.75 (+13.37%)

FCAU Fiat Chrysler
$9.86 /

-0.38 (-3.71%)

BNTX BioNTech
$70.80 /

+4.065 (+6.09%)

AXGN AxoGen
$11.60 /

+2.34 (+25.27%)

AKRO Akero Therapeutics
$32.03 /

+7.18 (+28.89%)

  • 06
    Feb
  • 10
    Oct
STZ Constellation Brands
$187.97 /

+13.54 (+7.76%)

PFE Pfizer
$34.14 /

+1.45 (+4.44%)

INO Inovio
$21.08 /

-5.8 (-21.58%)

GM General Motors
$25.13 /

-0.17 (-0.67%)

FDX FedEx
$159.00 /

+18.75 (+13.37%)

FCAU Fiat Chrysler
$9.86 /

-0.38 (-3.71%)

STZ Constellation Brands
$187.97 /

+13.54 (+7.76%)

SCS Steelcase
$10.67 /

-1.4 (-11.60%)

PFE Pfizer
$34.14 /

+1.45 (+4.44%)

INO Inovio
$21.08 /

-5.8 (-21.58%)

GM General Motors
$25.13 /

-0.17 (-0.67%)

FDX FedEx
$159.00 /

+18.75 (+13.37%)

FCAU Fiat Chrysler
$9.86 /

-0.38 (-3.71%)

BNTX BioNTech
$70.80 /

+4.065 (+6.09%)

AKRO Akero Therapeutics
$32.03 /

+7.18 (+28.89%)

FDX FedEx
$159.00 /

+18.75 (+13.37%)

STZ Constellation Brands
$187.97 /

+13.54 (+7.76%)

SCS Steelcase
$10.67 /

-1.4 (-11.60%)

PFE Pfizer
$34.14 /

+1.45 (+4.44%)

INO Inovio
$21.08 /

-5.8 (-21.58%)

GM General Motors
$25.13 /

-0.17 (-0.67%)

FDX FedEx
$159.00 /

+18.75 (+13.37%)

FCAU Fiat Chrysler
$9.86 /

-0.38 (-3.71%)

BNTX BioNTech
$70.80 /

+4.065 (+6.09%)

AKRO Akero Therapeutics
$32.03 /

+7.18 (+28.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.